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Abstract
Background: Chronic hyperglycemia enhances the formation of advanced glycation endproducts (AGEs) and
reactive oxygen species (ROS), contributing to diabetic complications. Thus, controlling blood glucose levels,
inhibiting the formation of AGEs and reducing ROS are key therapeutic targets in early stage type 2 diabetes.
Methods: The inhibitory effects of seven commercial liquid nutritional supplements against carbohydrate
hydrolysing enzymes, α-amylase and α-glucosidase, was determined by dinitrosalicylic (DNS) reagent and
p-nitrophenyl-α-D-glucopyranoside solution, respectively. Antiglycation activity was determined using the
formation of fluorescent protein-bound AGEs. Total phenolic and flavonoid content and antioxidant properties
(1,1-diphenyl-2-picrylhydrazyl antioxidant activity (DPPH) and ferric reducing antioxidant power (FRAP)) were
determined for correlation among these components and inhibitory activities.
Results: Samoan noni juice showed the greatest inhibitory effects against α-amylase, whereas chlorophyll
extracts showed the greatest inhibitory effect against α-glucosidase. Inhibition of α-glucosidase correlated
with TFC (r2 = 0.766; p < 0.01) and FRAP (r2 = 0.750; p < 0.01) whereas no correlation was observed for α-amylase
inhibition. All supplements inhibited fluorescent protein-bound AGEs, with the greatest effect exerted by Olive
Leaf Extract, Blood Sugar Support (IC50 = 0.5 mg/ml). The IC50 values negatively correlated with TPC (r
2 = −0.707;
p < 0.001) and DPPH scavenging activities (r2 = 0.515; p < 0.05).
Conclusion: The findings of this study highlight the potential of liquid nutritional supplements in managing and
treating type 2 diabetes mellitus.
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Background
The early stages of type 2 diabetes mellitus (T2DM) is
characterised by postprandial hyperglycemia due to in-
creased breakdown of starch by α-amylase, absorption of
glucose by α-glycosidase, insulin resistance and defects
with insulin secretion from beta cells of the pancreas
[1, 2]. If unmanaged, chronic hyperglycemia can pro-
mote protein glycation and the formation of advanced
glycation endproducts (AGEs). Protein glycation is ini-
tiated by the nucleophilic attack from a carbonyl group
of a reducing sugar to a free amine group present on
proteins, lipids and nucleic acids. This forms a freely
reversible Schiff base and rearranges to form a more
stable and irreversible ketoamine or Amadori product
that leads to the formation of AGEs [3, 4]. Elevated
levels of AGEs in the body contribute to diabetic com-
plications and age related disease by directly causing
the cross-linking of long lived proteins such as colla-
gen, leading to vascular stiffness and affecting vascular
structure and function. AGEs can also interact with
receptors, such as the receptor for AGEs, to induce
intracellular signalling that amplifies oxidative stress
and transcription of pro-inflammatory markers [1, 4].
Chronic hyperglycemia also promotes the formation of
free radicals, that further increases oxidative stress and
the formation of reactive oxygen species (ROS), which
in turn accelerates AGE formation [3, 5].
Improving glycaemic control and preventing postpran-
dial hyperglycemia is one of the main targets for the
treatment and management of the early stage of T2DM.
Salivary and pancreatic α-amylase and intestinal α-
glucosidase are responsible for the digestion and absorp-
tion of glucose from the diet. By inhibiting either of
these enzymes the amount of glucose absorbed into the
blood following a meal can be reduced, thus preventing
the postprandial surge in glucose and maintaining glu-
cose homeostasis [6, 7]. Acarbose, a synthetic drug and a
known α-glucosidase and α-amylase inhibitor, is cur-
rently prescribed to type 2 diabetic patients. Whilst
acarbose is effective in controlling blood glucose levels,
its adverse side effects includes gastrointestinal distur-
bances such as diarrhoea, flatulence and abdominal
distension [8]. Recently, there has been an increasing
search for natural alternatives including neutraceutical
formulations for their potent antioxidant activities and
health related benefits. Polyphenols, abundant in plant
based foods and beverages, are well known for their po-
tent antioxidant effects [9, 10]. Recent studies have also
shown polyphenols from plant extracts to be effective
inhibitors of α-amylase [11, 12], α-glucosidase [11, 12]
and protein glycation based on in vitro and in vivo
studies [5, 13, 14].
Liquid nutritional supplements, a class of neutraceuti-
cals including herbal extracts and plant-based extracts,
claim to contain high levels of polyphenols and may be a
suitable and cost-effective alternative to synthetic
drugs. Very little scientific evidence exists concerning
dietary supplements and their health benefits, and
none to our knowledge on commercial liquid nutri-
tional supplements on their potential role in the
management of hyperglycemia and T2DM. Thus, this
study was aimed to investigate the inhibitory effect of
commonly consumed liquid nutritional supplements
against α-amylase, α-glucosidase, and AGE formation
using in vitro model. Total phenolic and flavonoid
content, and antioxidant properties were evaluated for




Chemicals and solvents were purchased from Sigma-
Aldrich (Sydney, Australia) unless otherwise specified.
All chemicals were either analytical or HPLC grade.
Samples
Liquid nutritional supplements, purchased from local
retailers and online included: Acai Power, Acai Juice Blend
(APNG, containing acai concentrate, pear and cherry
juice); Chlorophyll, Detox Health Drink (CHC, containing
chlorophyll powder); Olive Leaf Extract, Natural High
Strength (OLE01, containing olive leaf extracts with
4.4 mg/ mL oleuropein); Olive Leaf Extract, High
Strength, (OLE02, containing olive leaf extracts with
4.4 mg/mL oleuropein and mixed berries); Olive Leaf
Extract, Blood Sugar Support (OLE03, containing olive
leaf extracts with 4.4 mg/mL oleuropein and 0.25 mg/mL
hydroxytyrosol); Noni Juice, Samoan (NJ01, containing
100 % noni fruit extracts); Fijian Noni (NJ02, containing
100 % Fijian noni extracts).
Inhibition of α-amylase assay
The α-amylase inhibitory action was determined as
described previously with some modifications [15].
Samples (125μL, 1 mg/mL) were incubated with por-
cine pancreatic α-amylase solution (125μL, 0.5 mg/mL
in 0.1 M phosphate buffer saline (pH 6.9)), at 37 °C for
10 min. After pre-incubation starch solution (125μL,
1 %) was added at timed intervals (~30μL every 10 s)
and the reaction mixture was further incubated at 37 °C
for 30 min. The reaction was stopped by adding DNS
reagent (250μL, containing 1 % 3,5-dinitrosalicylic acid,
0.2 % phenol, 0.5 % sodium sulphite and 1 % sodium
hydroxide) and heating in a boiling water bath (100 °C)
for 10 min. After boiling the colour was stabilized with
the addition of potassium sodium tartarate solution
(250μL, 40 %). The mixture was cooled to room
temperature and the absorbance was measured at
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540 nm. Acarbose was used in the assay as positive con-
trol. Inhibitory activity was expressed as % inhibition
= ((Acontrol – Asample)/Acontrol) × 100.
Inhibition of α-glucosidase assay
The α-glucosidase inhibitory action was determined as
described previously with some modifications [15].
Diluted samples (50μL, 1 mg/mL) and α-glucosidase
solution (100μL, 0.2 units/mL in 0.1 M phosphate
buffer (pH 6.9)), were mixed in a 96 well plate and
incubated at 37 °C for 30 min. After pre-incubation, p-
nitrophenyl-α-D-glucopyranoside solution (50μL, 5 mM
in 0.1 M phosphate buffer (pH 6.9)), was added to the re-
action mixture and incubated at 37 °C for 30 min. Sodium
carbonate solution (60 μL, 0.1 M) was added and the reac-
tion mixture was further incubated at 37 °C for 20 min.
Absorbance was measured at 450 nm. Acarbose was used
as a positive control. Inhibitory activity of α-glucosidase
was expressed as the % inhibition = (Acontrol – Asample)/
Acontrol) × 100.
Fluorescence AGE formation assay
Fluorescent protein-bound AGEs were measured ac-
cording to a previous method with modification [5].
Briefly, 1000μL of bovine serum albumin (BSA, 10 mg/
mL final concentration), prepared with 0.2 M phos-
phate buffer (pH 7.4), was incubated with nutritional
supplements (200μL, 0.5-5 mg/mL final concentration)
at room temperature for 30 mins. After pre-incubation,
glucose (800μL, 100 mM final concentration) was
added to each reaction vessel, flushed with nitrogen
and incubated at 37 °C for 3 weeks. Aminoguanidine
(30μM final concentration) was included as a positive
control. All reaction vessels contained 0.02 % sodium
azide (final concentration) to prevent any microbial
growth. After 3 weeks incubation, protein was isolated
by slowly adding trichloroacetic acid (400μL, 20 %) to
500μL of glycated sample. The mixture was kept on ice
for 10 min before centrifugation (10000 × g) for 10
mins. Pellet was dissolved in alkaline phosphate buffer
(1000μL, 0.2 M, pH 10) and fluorescence was read at
excitation and emission wavelengths of 370 nm Ex and
440 nm, respectively. Percent inhibition was deter-
mined and IC50 values were calculated as % inhibition
= ((Fnegative control – Fsample)/Fnegative control) × 100.
Total phenolic and total flavonoid content
Total phenolic content was determined using Folin–
Ciocalteu assay and total flavonoid content was deter-
mined by aluminium chloride colorimetric technique as
described previously [16].
Determination of 1,1-diphenyl-2-picrylhydrazyl antioxidant
activity (DPPH)
The radical scavenging activity was measured accord-
ing to an assay described previously with modifications
[15]. Briefly, diluted samples (50μL, 0.5–5 mg/mL)
were added with DPPH (150μL, 0.2 mM) and incu-
bated for 30 min in the dark. After incubation the
absorbance was measured at 490 nm. Butyl hydroxyl
toluene (BHT, 500μg/mL) was used as a positive con-
trol. DPPH activity was expressed as percent inhibition
(%) = ((Acontrol – Asample)/Acontrol × 100).
Determination of ferric reducing antioxidant power (FRAP)
The reducing power of the samples was determined as
described previously [17]. Ascorbic acid (0-250μg/mL)
was used to develop a standard curve and results
calculated and expressed as ascorbic acid equivalents
(μg AAE/g).
Statistical analysis
Results were expressed as the mean ± standard deviation
(SD) or standard error of the mean (SEM) from three in-
dependent experiments. IC50 values were calculated by
non-linear regression using Graphpad Prism Version 6.0
for Windows. One-way analysis of variance (ANOVA)
was determined using Tukey’s or Dunnet’s multiple
comparison tests and linear relationship was determined
with Pearson’s correlation coefficient (r2). Difference
were considered to be significant at p < 0.05.
Results and discussion
Natural products containing polyphenols and antioxi-
dants may be an effective way of reducing oxidative
stress and delaying the onset of diabetic complications.
Dietary or nutritional supplements are commonly used
for general wellness and prevention of disease. Nutri-
tional supplements including herbal extracts and fruit
juices may contain pharmacoactive components, and
whilst manufacturers claim that these components pro-
vide health benefits, very little scientific evidence is avail-
able to-date to support these claims. In this study we
aimed to investigate the antiglycation, α-amylase and α-
glucosidase inhibitory potential of selected liquid nutri-
tional supplements.
α-amylase and α-glucosidase inhibition
One of the primary targets for the management of early
stage T2DM is to maintain steady blood glucose levels
and prevent the postprandial surge of glucose, and an
effective way of achieving this is by inhibiting α-
amylase or α-glucosidase [7]. In our study, α-amylase
and α-glucosidase inhibitory potential of liquid nutri-
tional supplements were compared with a positive
control (acarbose). Inhibition of α-amylase ranged from
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15.22 ± 1.46 to 24.14 ± 2.23 % (Fig. 1). Samoan noni
juice (NJ01) showed moderate but significant α-amylase
inhibition (p < 0.001) whereas APNG and CHC showed
no difference when compared to acarbose. Olive leaf sup-
plements (OLE01, OLE02 and OLE 03) showed similar
level of inhibition and were significantly higher (p < 0.01)
than acarbose. Our study supports the findings of Komaki
and co-workers [18] who found ethanolic extracts of olive
leaf to effectively inhibit α-amylase and determined
oleuropein to be one of the main phenolic compounds
responsible for this inhibitory effect. In our study, all
olive leaf supplements contained 4.4 mg/mL of oleuro-
pein (determined on the product label). A previous
study using noni juice when taken twice a day for
20 days also demonstrated hypoglycaemic effects in dia-
betic rats but α-amylase levels were not measured [19].
Inhibition of α-glucosidase ranged from 10.33 ± 0.25 to
35.29 ± 0.93 %, with CHC showing the highest inhibition
(Fig. 1). All olive leaf supplements (OLE01, OLE02 and
OLE03) demonstrated inhibitory effects that were sig-
nificantly greater than acarbose. APNG, NJ01 and NJ02
exhibited inhibitory activity at levels similar to that of
acarbose. Previous reports have shown the use olive leaf
extracts for improving diabetic complications [20, 21],
however, this is the first study to report on α-glucosidase
inhibitory activity by chlorophyll and olive leaf extracts.
Previous studies investigated various plant and fruit ex-
tracts for the inhibition of α-glucosidase and attributed
their potential inhibitory activities to anthocyanin con-
tent [12, 22]. In our study, CHC extract contained
chlorophyll including anthocyanin, ascorbic acid and
potassium sorbate, which may have played a role in its
inhibitory effects. Isolation of key components from
CHC and their enzyme inhibitory potentials needs fur-
ther investigation. Another limitation in our study was
that the inhibitory potential against both enzymes were
investigated only at one concentration thus a concentra-
tion dependent study would allow comparisons with
other studies and known inhibitors.
Antiglycation
The use of pharmacological compounds that could in-
hibit the formation of AGEs is another approach in
delaying or preventing the onset of diabetic complica-
tions. Aminoguanidine, a well investigated inhibitor of
protein glycation prevents AGE formation by reacting
with carbonyl groups on reducing sugars [3] however
this clinical inhibitor has numerous side effects [23]. In
our study, the inhibitory potential of liquid nutritional
supplements on fluorescent protein-bound AGEs was
explored using BSA-glucose models. IC50 values ranged
from 0.5 ± 0.03 to 4.70 ± 0.67 mg/mL (Table 1).
OLE03 showed to be the most effective inhibitor with
the lowest IC50. These results support the findings of a
previous study which found methanolic olive leaf extract
to be a successful inhibitor of protein glycation in BSA-
ribose models (3 weeks incubation), inhibiting fluores-
cent AGE formation [24]. The authors suggested that
luteolin, luteolin-4’-O-β- D-glucopyranoside, oleuropein
and hydroxytyrosol may be responsible for the inhibitory
effect. In our study, olive leaf supplement (OLE03) sold
as blood sugar support supplement contained oleuropein
Fig. 1 The percentage inhibition of liquid dietary supplements on α-amylase and α-glucosidase activity. Values are expressed as mean ± SEM, n = 3.
*p < 0.05, **p < 0.01, ***p < 0.001 are significant different when compared to α-amylase values for acarbose. #p < 0.05, ## p < 0.01, ###p < 0.001 are
significantly different when compared to α-glucosidase values for acarbose. Supplements include acai powder (APNG), chlorophyll (CHC), olive leaf
extracts (OLE01, OLE02 OLE03) and noni juice (NJ01, NJ02)
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(4.4 mg/mL) and hydroxytyrosol (250 μg/mL) that may
have contributed to lower AGE formation.
Correlations between inhibitory activities and phenolic or
flavonoid or antioxidant activities
TPC ranged from 0.48 ± 0.03 to 3.00 ± 0.36 mg GAE/
mL whereas TFC ranged from 0.06 ± 0.03 to 1.52 ±
0.97 mg QE/mL in liquid nutritional supplement
(Table 1). The free radical scavenging activities of liquid
nutritional supplements showed a dose dependent re-
sponse (Fig. 2). FRAP values ranged from 0.73 ± 0.06 to
3.16 ± 0.14 mg AAE/mL of sample (Table 1). Pearson’s
correlation analysis detected several significant relation-
ships among the investigated variables. Correlation ana-
lysis showed DPPH free radical scavenging activity to be
positively correlated with TPC (r2 = 0.6329, p = 0.0021)
but not with TFC. Interestingly, FRAP results showed a
strong positive correlation with TPC (r2 = 0.647, p < 0.001)
and TFC (r2 = 0.840, p < 0.0001). These relationships show
that the total phenolic content defines their antioxidant
activities.
The α-amylase inhibition did not correlate with TPC,
TFC or antioxidant activities however, α-glucosidase
inhibition positively correlated with TFC (r2 = 0.766,
p < 0.01) and FRAP (r2 = 0.750, p < 0.01) (Table 2). There
was no significant correlation between α-glucosidase in-
hibition and TPC or DPPH scavenging activity (Table 2).
Various levels of correlation between TPC, TFC and
antioxidant activities and enzyme inhibition are reported
in the literature. For example, no linear relationship was
identified between α-glucosidase inhibitory activities of
native Australian herb fractions and their FRAP values
[25]. A moderate positive relationship between TPC and
α-glucosidase inhibition for commonly used medicinal
plants (r2 = 0.393) and herbal teas (r2 = 0.371) has been
reported [26]. In the present study, the result shows
different affinities of evaluated variables to enzyme in-
hibition that relates to different relationships reported in
the literature, suggesting that the total phenolic,
flavonoids and their antioxidant capacities do not always
define enzyme inhibitory activities. IC50 values for fluor-
escent AGE inhibitions negatively correlated with TPC
(r2 = −0.707, p < 0.001) and DPPH scavenging activity
(r2 = −0.515, p < 0.05). Positive relationships were ob-
served with wild berries, where % AGE inhibition cor-
related with TPC (r2 = 0.760) and DPPH (r2 = 0.452) [5].
Antiglycation agents may exert their effects by blocking
free amino groups on proteins, or carbonyl groups on
reducing sugars so that they cannot bind; acting as
Table 1 Total phenolic content, total flavonoid content, ferric










APNG 1.77 ± 0.12b 0.86 ± 0.35b 2.52 ± 0.16c 2.84 ± 1.01c
CHC 2.35 ± 0.09c 1.15 ± 0.29c 3.16 ± 0.14d 1.60 ± 0.57bc
OLE01 1.98 ± 0.06bc 1.03 ± 0.21b 2.01 ± 0.25b 2.14 ± 0.21bc
OLE02 2.65 ± 0.13d 1.52 ± 0.12c 1.70 ± 0.06b 1.03 ± 0.10ab
OLE03 3.00 ± 0.36e 1.57 ± 0.97c 1.95 ± 0.17b 0.50 ± 0.03a
NJ01 0.48 ± 0.03a 0.09 ± 0.00a 0.73 ± 0.06a 4.70 ± 0.67d
NJ02 0.05 ± 0.02a 0.06 ± 0.03a 0.94 ± 0.08a 1.89 ± 0.43bc
Data values are expressed as mean ± SD, n = 3. Different superscripts indicate
significant difference (p < 0.05) within each column. Supplements include acai
powder (APNG), chlorophyll (CHC), olive leaf extracts (OLE01, OLE02 OLE03)






















Fig. 2 The percentage inhibition of liquid dietary supplements on 1,1-diphenyl-2-picrylhydrazyl antioxidant activity (DPPH). Values are expressed
as mean ± SD, n = 3. Samples include acai powder (APNG), chlorophyll (CHC), olive leaf extracts (OLE01, OLE02 OLE03), noni juice (NJ01, NJ02) and
Butyl hydroxyl toluene (BHT)
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antibodies to block Amadori products; as enzymes
deglycating Amadori products and intermediates; and
chelating transition metals, reducing glycation-derived
free radicals [3]. In our study antiglycation activity cor-
related with TPC and DPPH, suggesting that phenolic
compounds may protect against glycation; preventing
the conversion of Amadori products into AGEs that oc-
curs in the presence of transition metals and oxygen.
Conclusion
Commercial nutritional supplements analysed in this study
exhibited different levels of inhibitory activity against α-
amylase, α-glucosidase and protein-bound AGEs. While
some supplements were more effective than others these
inhibitory activities did not always correlate with phenolic
content, flavonoid or antioxidant activities, suggesting that
the inhibition may occur via different pathways. This study
highlights promising potential of liquid nutritional supple-
ments as a therapeutic approach to managing T2DM. As
this study was the first to investigate antiglycation potential
of liquid nutritional supplements, it provides opportunity
to explore more neutraceutical supplements and their rele-
vant metabolites in cells, animal or humans to determine
the bioavailability and the mechanism of action.
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